- Open Access
Correction to: Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma
BMC Cancer volume 19, Article number: 1238 (2019)
- The original article was published in BMC Cancer 2018 18:1152
Correction to: BMC Cancer
As a result of an author oversight in the original article , the legend of Figure 5A and C is inaccurate and one panel in Figure 5C (FOXM1N H929 cells shown in the top row, left) is wrong. The mistakes have now been corrected in Figure 5C appended below and in the amended legend to Figure 5A and C below. Importantly, the main text of the paper and the results and conclusions described therein are not affected by this correction. We sincerely apologize to the readership of BMC Cancer for any confusion the oversight may have caused.
Amended legend to Figure 5:
(A) Western analysis of Rb and pRb levels in paired FOXM1Hi and FOXM1N myeloma cells (left) and paired FOXM1KD and FOXM1N myeloma cells (right).
(C) Depicted to the left is the elevation of β-galactosidase (β-gal) activity, a classic phenotype of cellular senescence, in FOXM1KD H929 cells (bottom) relative to FOXM1N controls (top). Cells were not treated with drug in both cases. The result was confirmed using paired FOXM1KD / FOXM1N ARP1 samples (not shown). Depicted to the right is the increased proportion of β-gal+ XG1 cells following treatment with Dox. FOXM1Hi cells exhibited a lesser increase than FOXM1N cells. Cells were evaluated using an Olympus BX-51 Light Microscope equipped with an UPLSAPO objective (Olympus) of 40x magnification and 0.95 numerical aperture. The imaging medium was air. The light temperature of the microscope bulb varied between 3000 and 3400 K. Images were acquired with the help of a DP2 digital camera (Olympus) and DP2-BSW imaging software (Olympus), saved as TIF data files, and enhanced—with respect to brightness, contrast, and color balance—using the Adobe Photoshop CS2 Version 9.0.2 software (Adobe Systems, Inc).
Gu, et al. Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma. BMC Cancer. 2018;18:1152 https://doi.org/10.1186/s12885-018-5015-0.
About this article
Cite this article
Gu, C., Jing, X., Holman, C. et al. Correction to: Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma. BMC Cancer 19, 1238 (2019). https://doi.org/10.1186/s12885-019-6443-1